Kynmobi is a drug owned by Sumitomo Pharma America Inc. It is protected by 19 US drug patents filed from 2020 to 2022. Out of these, 12 drug patents are active and 7 have expired. Based on its patents and exclusivities, its generic launch date is estimated to be Apr 19, 2036. Details of Kynmobi's patents and their expiration are given in the table below.

A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Kynmobi's patents.

Latest Legal Activities on Kynmobi's Patents

Given below is the list of recent legal activities going on the following patents of Kynmobi.

Activity	Date	Patent Number
Today's Critical Events
Payment of Maintenance Fee, 8th Year, Large Entity	03 Nov, 2023	US9326981
Payment of Maintenance Fee, 8th Year, Large Entity	15 Sep, 2023	US9283219
Payment of Maintenance Fee, 4th Year, Large Entity	24 Apr, 2023	US10449146
Payment of Maintenance Fee, 4th Year, Large Entity	24 Mar, 2023	US10420763
Change in Power of Attorney (May Include Associate POA) Critical	10 Mar, 2023	US8414922
Change in Power of Attorney (May Include Associate POA) Critical	10 Mar, 2023	US11419769
Change in Power of Attorney (May Include Associate POA) Critical	10 Mar, 2023	US9283219
Change in Power of Attorney (May Include Associate POA) Critical	10 Mar, 2023	US10959943
Change in Power of Attorney (May Include Associate POA) Critical	10 Mar, 2023	US10449146
Correspondence Address Change Critical	09 Mar, 2023	US10959943

While patent expiration is one way of estimating the generic date of a drug, if a patent gets invalidated somehow, the generic of the drug may arrive early. Being aware of all relevant patents can help in avoiding legal pitfalls. Given below are details of the litigation history of Kynmobi and ongoing litigations to help you estimate the early arrival of Kynmobi generic.

Kynmobi's Litigations

Kynmobi been subject to various legal proceedings, including patent litigations. The earliest legal proceeding was initiated on Oct 28, 2014, against patent number US8765167. The petitioner BioDelivery Sciences International, Inc., challenged the validity of this patent, with MonoSol Rx, LLC. as the respondent. Click below to track the latest information on how companies are challenging Kynmobi's patents.

Patent	Proceeding Filing Date	Status	Respondent	Petitioner
Live updates
US8603514	June, 2017	Institution Denied (20 Oct, 2017)	MonoSol Rx, LLC et al.	Par Pharmaceutical, Inc. et al.
US8603514	June, 2017	Terminated-Denied (20 Oct, 2017)	MonoSol Rx, LLC	Par Pharmaceutical, Inc.
US8603514	June, 2017	Institution Denied (20 Oct, 2017)	MonoSol Rx, LLC et al.	Dr. Reddy’s Laboratories, Inc. et al.
US8603514	June, 2017	Terminated-Denied (20 Oct, 2017)	MonoSol Rx, LLC	Dr. Reddy’s Laboratories, Inc.
US8603514	November, 2016	Terminated-Settled (06 Oct, 2017)	MonoSol Rx, LLC et al.	Mylan Technologies, Inc. et al.
US8603514	May, 2016	Institution Denied (05 Dec, 2016)	MonoSol Rx, LLC et al.	Dr. Reddy's Laboratories, Inc. et al.
US8603514	May, 2016	Terminated-Denied (05 Dec, 2016)	MonoSol Rx, LLC	Dr. Reddy's Laboratories, Inc.
US8603514	December, 2015	Institution Denied (23 May, 2016)	MONOSOL RX LLC et al.	Teva Pharmaceuticals USA Inc
US8603514	December, 2015	Terminated-Denied (23 May, 2016)	MONOSOL RX LLC	Teva Pharmaceuticals USA Inc
US8765167	October, 2014	Final Written Decision (24 Mar, 2016)	MonoSol Rx, LLC. et al.	BioDelivery Sciences International, Inc.
US8765167	October, 2014	FWD Entered (24 Mar, 2016)	MonoSol Rx, LLC.	BioDelivery Sciences International, Inc.
US8765167	October, 2014	Terminated-Settled (24 Mar, 2016)	MonoSol Rx, LLC. et al.	BioDelivery Sciences International, Inc.
US8765167	October, 2014	Institution Denied (20 May, 2015)	MonoSol Rx, LLC. et al.	BioDelivery Sciences International, Inc.
US8765167	October, 2014	Terminated-Denied (20 May, 2015)	MonoSol Rx, LLC.	BioDelivery Sciences International, Inc.

FDA has granted some exclusivities to Kynmobi. Till the time these exclusivities are active, no other company can market a generic or bioequivalent version of Kynmobi, regardless of the status of it's patents. These exclusivities hence play a crucial role in delaying the generic launch. Given below are details of the exclusivities granted to Kynmobi.

Stay ahead of others in designing the generic launch strategy of these 5 blockbuster drugs expiring in next 5 years.

Get the exclusive patent insights now. Don't be the last to know.

Download Report

Several oppositions have been filed on Kynmobi's European patents. EP oppositions can significantly impact the timeline for the generic launch of drugs. If an opposition results in the revocation or amendment of a patent, it can shorten the exclusivity period of the original drug. This can lead to an earlier entry of generic versions into the market. To help you estimate the potential early arrival of Kynmobi's generic, the next section provides detailed information on ongoing and past EP oppositions related to Kynmobi patents.

Kynmobi's Oppositions Filed in EPO

Kynmobi has faced multiple oppositions in the European Patent Office. The earliest opposition was filed on Sep 11, 2012, by Lts Lohmann Therapie-Systeme Ag. This opposition was filed on patent number EP02801042A. Click below to reveal the latest opposition data.

Application	Filing Date	Opposition Party	Legal Status
Live updates
EP15175258A	May, 2019	D Young & Co LLP	Granted and Under Opposition
EP10786915A	May, 2016	LTS LOHMANN Therapie-Systeme AG	Granted and Under Opposition
EP10786915A	May, 2016	Generics (U.K.) Limited	Granted and Under Opposition
EP11157819A	Jun, 2014	Ahrens, Gabriele	Patent maintained as amended
EP02782151A	Jun, 2013	Acino Pharma AG	Revoked
EP02782151A	Jun, 2013	Germann, Sandra	Revoked
EP02801042A	Sep, 2012	Ahrens, Gabriele	Patent maintained as amended
EP02801042A	Sep, 2012	LTS LOHMANN Therapie-Systeme AG	Patent maintained as amended

US patents provide insights into the exclusivity only within the United States, but Kynmobi is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Kynmobi's family patents as well as insights into ongoing legal events on those patents.

Kynmobi's Family Patents

Kynmobi has patent protection in a total of 25 countries. It's US patent count contributes only to 42.2% of its total global patent coverage. 4 countries have all of their patents expired or invalidated which has opened up potential generic launch opportunities in these countries. Click below to unlock the full patent family tree for Kynmobi.

Unlock Global Patents

Generic Launch

About Kynmobi

Kynmobi is a drug owned by Sumitomo Pharma America Inc. It is used for managing 'off' episodes in patients with Parkinson's disease. Kynmobi uses Apomorphine Hydrochloride as an active ingredient. Kynmobi was launched by Sumitomo Pharma Am in 2020.